中文 | ENG

第58卷 第1期 2025-1
Ensuring authorship qualification in clinical research articles: A focus on surgical therapy studies

.........................

第58卷 第1期 2025-1
Estimated risk for transfusion of monkeypox contaminated perioperative blood transfusion: A call to action for stronger regulations and testing protocols

.........................

第58卷 第1期 2025-1
Insights into traumatic and crisis surgery: Implications of data analysis in conflict zones

.........................

第58卷 第1期 2025-1
Tongue peeling as an adverse reaction with use of micronized purified flavonoid: A case report

.........................

第58卷 第1期 2025-1
Pilonidal sinus of scrotum: A rare clinical entity

.........................

第58卷 第1期 2025-1
Incidental autopsy finding of retiform hemangioendothelioma of the spleen

.........................

第58卷 第1期 2025-1
Retroperitoneal laparoscopy for hydronephrosis due to multiple fibroepithelial polyps: A case series

.........................

第58卷 第1期 2025-1
Case reports of type 1 cystic biliary atresia—A rare variant of biliary atresia alongwith reviewof literature

.........................

第58卷 第1期 2025-1
The predictors of intraoperative surgical expenses in liver resection for hepatocellular carcinoma

.........................

第58卷 第1期 2025-1
Intracorporeal anastomosis versus extracorporeal anastomosis following laparoscopic right hemicolectomy: Surgical outcomes of a single-center observational study

.........................

第58卷 第1期 2025-1
Quality of life and spiritual health in motorcycle accident survivors: An analysis using the SF-36 Questionnaire and Spiritual Scale

.........................

第58卷 第1期 2025-1
Plastin 3 expression in circulating tumor cells as a predictor of cancer status in patients with prostate cancer

.........................

第57卷 第6期 2024-11
Emerging robot-guided techniques in endodontic microsurgery

.........................

第57卷 第6期 2024-11
Management of subcapsular hematoma after living donor liver transplant

.........................

第57卷 第6期 2024-11
Urethral pseudodiverticulum with left-sided nonfunctioning kidney: Case report

.........................

第57卷 第6期 2024-11
Strategy to minimize surgical defect of dermatofi brosarcoma protuberans

.........................

第57卷 第6期 2024-11
Rapunzel syndrome—An uncommon disease with varied common presentations

.........................

第57卷 第6期 2024-11
Minimally invasive approaches to management of acute necrotizing pancreatitis

.........................

第57卷 第6期 2024-11
Innovative surgical technique: Addressing ethical concerns

.........................

第57卷 第6期 2024-11
Emergency surgery and HIV screening, clinical or universal scenarios?

.........................
登入帳號才能閱讀全文
 
篇名 Eighty percent partial splenic embolization is a safe and effective procedure in management of cirrhotic hypersplenism
作者 Bor-Gang Wu, Andy Shau-Bin Chou, Guan-Jin Ho, Ming-Che Lee
卷期/出版年月 50卷3期 (2017/6)
頁次 101-106
摘要 Background: Partial splenic embolization (PSE) has been proposed in patients with cirrhotic hypersplenism in cases when thrombocytopenia causes clinical manifestations or if there are contraindications to subsequent therapeutic procedures. We provide a retrospective review of the safety and favorable treatment results of 80% splenic embolization in patients with cirrhotic hypersplenism in our institute. Methods: Thirteen consecutive patients with cirrhotic hypersplenism were included in a 4‑year study period. The indications for PSE were as follows: percutaneous treatment of hepatocellular carcinoma (HCC) (n = 3), transarterial chemoembolization plus hepatic arterial infusion chemotherapy for HCC (n = 2), preparation for major surgery (n = 5), and severe purpura (n = 3). PSE was performed with up to 80% reduction of splenic blood flow by radiological intervention. A tight protocol of prophylactic antibiotics was introduced. Patient demographics, procedure‑related complication, and efficacy of PSE were analyzed. Results: The mean follow‑up time was 26.1 ± 12.3 months. All the patients tolerated the procedure. The minor complication of postembolization syndromes such as fever and abdominal pain occurred in 38.5% and 61.5% of patients, respectively. Only a major complication of transient ascites needs diuretic therapy occurred in two patients. Pre‑PSE platelet count was 35,077 ± 11,049/mm3, and it significantly increased 1 week after PSE, with a mean increase of platelet count to 384% of pre‑PSE level (P < 0.001). The effect of PSE sustained to maintain the platelet count significantly at a mean level of 112,636 ± 33,341/mm3, 114,571 ± 30,696/mm3, and 118,000 ± 31,035/mm3 at 12, 24, and 36 months, respectively. Conclusion: Our series demonstrated that 80% PSE is a safe and effective method to treat patients with cirrhotic hypersplenism. It could not only increase the platelet count within a short period of time but also maintain it at an acceptable level for a long duration. Under a tight protocol of prophylactic antibiotic and delicate technique of PSE, there was no any septic complication developed in our series.
關鍵詞 Cirrhosis, complication, hypersplenism, splenic embolization, thrombocytopenia
分類 Original Article

台灣外科醫學會雜誌 © 2006 Taiwan Surgical Association All Rights Reserved
會 址:台北市南京東路五段 31 號 3 樓
電 話:(02) 2769-7845 傳 真:(02) 2746-7149 Email: journal@surgery.org.tw